Enriching BODIPY Triplet States via Ruthenium(II) Conjugation for Improved Photodynamic Therapy.

Photodynamic therapy (PDT) is increasingly recognized as a minimally invasive and highly targeted cancer treatment, leveraging light-activated photosensitizers to produce cytotoxic reactive oxygen species (ROS). Among emerging candidates, ruthenium-BODIPY (boron-dipyrromethene) dyads have attracted growing interest due to their unique ability to synergize the photophysical and photobiological strengths of both components. These conjugates exhibit tunable absorption, enhanced cellular uptake, and efficient ROS generation, effectively overcoming several drawbacks of traditional photosensitizers. This perspective explores the recent advances in the design of Ru-BODIPY dyads, with a focus on their structure-property relationships, subcellular behavior, and light-triggered cytotoxicity under both normoxic and hypoxic environments. By drawing on concepts from photochemistry, coordination chemistry, and bioinorganic science, we highlight how these dyads are shaping the development of next-generation PDT agents. Finally, we discuss key challenges and future opportunities for clinical translation, including strategies for targeted delivery, treatment of deep-seated tumors, and integration with multimodal therapies.